At Acadia, we remain deeply committed to providing important new therapies to patients and delivering value for our stockholders. Our Investor Center is designed to provide you with convenient access to company information.

Recent News

- Pimavanserin as an adjunct to an antipsychotic showed significant improvements in the negative symptoms of schizophrenia vs. antipsychotic treatment alone - Pimavanserin well-tolerated among study participants SAN DIEGO --(BUSINESS WIRE)--Dec. 1, 2021-- Acadia Pharmaceuticals Inc.
- Yours, Truly Debuts During National Family Caregivers Awareness Month to Encourage the Parkinson’s Disease Community to Preserve and Share Stories and Memories of Their Loved Ones SAN DIEGO --(BUSINESS WIRE)--Nov. 16, 2021-- Acadia Pharmaceuticals Inc.
- 3Q21 net sales of $131.6 million , a 9% increase over 3Q20 - FDA meeting scheduled to discuss next steps towards a resubmission of the pimavanserin sNDA SAN DIEGO --(BUSINESS WIRE)--Nov. 8, 2021-- Acadia Pharmaceuticals Inc. (Nasdaq: ACAD), today announced its financial results for the third